Mode
Text Size
Log in / Sign up
Phase 4 N=20 Prevention

Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study

Contraception

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcome: Primary: Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire) — 9; 8 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Etonogestrel contraceptive implant (Drug)
Age
Pediatric, Adult · 16+ yrs
Sex
Female
Sponsor
University of California, Davis
Primary completion
Jul 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Evaluating ENG as Acceptable: Acceptability (Measurement: Questionnaire)
9; 8
PRIMARY
Number of Participants Evaluating ENG as Tolerable: Tolerability (Measurement: Diaries and Questionnaire)
2; 0; 1; 0; 1; 0
SECONDARY
Patient Interest (Measurement: Ability to Enroll)
10; 10
SECONDARY
Bleeding Patterns (Measurement: Diaries)
1; 1; 2; 1; 2; 2
SECONDARY
COC Continuation Rate (Measurement: Participant Interview)
6; 5
SECONDARY
Post-study Method Plan (Measurement: Participant Interview)
3; 4; 1; 3; 5; 2

Summary

Women currently using or starting a combined oral contraceptive will be offered study enrollment. Study subjects will have a Nexplanon placed and followed for 6 months to evaluate if they continue the COC, continue the implant, or both, and to assess adverse events and bleeding patterns.

Eligibility Criteria

Inclusion:

  • Women being seen in a UC Davis medical office or who contact our research office.
  • Potential participants must be women currently COCs or intending to initiate COCs at the time of the office visit.

Exclusion:

  • Women who have contraindications to using a COC or a contraceptive implant (Category 3 or 4 in the CDC Medical Eligibility Criteria) will be excluded.
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02852265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search